Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

PASADENA, Calif.–(BUSINESS WIRE)–Apr. 7, 2024– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials